0001599298-26-000039
SEC filingSummit Therapeutics reported a sharply higher net loss of $189.4 million in Q1 2026, driven by increased stock-based compensation and clinical trial costs, while cash burn accelerated and the company reiterated its going concern warning.
Summit's lead asset, ivonescimab, is a bispecific PD-1/VEGF antibody in-licensed from Akeso. In Q4 2025, the company submitted a Biologics License Application (BLA) for ivonescimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC) after progression on a third-generation TKI. The FDA accepted the filing in January 2026 with a PDUFA goal date of November 14, 2026. However, the FDA noted that a statistically significant overall survival (OS) benefit is necessary for marketing authorization, and the progression-free survival (PFS) results from the HARMONi study may not be sufficient. The HARMONi study showed a PFS hazard ratio of 0.52 (p<0.00001) but OS did not reach statistical significance (HR 0.79, p=0.057). A subsequent ad hoc OS analysis with longer Western patient follow-up showed an improved nominal p-value (HR 0.78, p=0.0332). Enrollment in the squamous cohort of HARMONi-3 completed in Q1 2026, with a final PFS analysis expected in the second half of 2026. Enrollment in the non-squamous cohort is expected to complete by end of Q2 2026, with PFS analysis in the first half of 2027. The company also initiated HARMONi-7 (ivonescimab monotherapy vs. pembrolizumab in first-line high PD-L1 NSCLC) and HARMONi-GI3 (first-line metastatic CRC).
Summit expects R&D and G&A expenses to continue increasing as it progresses clinical development and scales infrastructure. The company has no approved products and no revenue, relying entirely on external financing. Key risks include the FDA's requirement for statistically significant OS data for the BLA, potential delays in trial enrollment or data readouts, the need for substantial additional capital, and ongoing litigation related to the December 2022 notes. A European patent opposition against the ivonescimab patent was filed in June 2025, though the company contests the claims.